Juno Lighting Inc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (104)

Latest Posts

About This Stock More About This Stock
Week In Review: Innovent Out-Licenses Ex-China Rights For PD-1 To Lilly In $1 Billion Deal
Article By: ChinaBio® Today
Saturday, August 22, 2020 1:53 PM EDT
Suzhou Innovent Bio expanded its 2015 alliance with Eli Lilly for Tyvyt®, Innovent's anti-PD-1 immunotherapy. In return for a $1+ billion package, Lilly will have an exclusive license to develop Tyvyt in ex-China markets.
In this article: HBM, LLY, BAYN, BAYN, JUNO, JD, EYPT
Read
Week In Review: BeiGene Signs $540 Million Deal For China Rights To Three HBV Candidates
Article By: ChinaBio® Today
Saturday, July 25, 2020 1:21 PM EDT
Beijing's BeiGene in-licensed Greater China rights to three inhibitors for chronic hepatitis B virus from Assembly Bio in a $540 million agreement. BeiGene, which will make a $40 million upfront payment, is responsible for $500 million in milestones.
In this article: CASI, JUNO, HCM, BGNE, ASMB
Read
Week In Review: Suzhou Innovent Announces $2 Billion Immunotherapy Collaboration With Roche
Article By: ChinaBio® Today
Saturday, June 13, 2020 1:32 PM EDT
Suzhou Innovent Bio formed a far-reaching R&D collaboration with Roche that has a potential value of over $2 billion. Roche will have an option to license each product for ex-China development and commercialization.
In this article: RHHBY Also: LLY, SNY, BRN, JUNO
Read
Clovis: Evaluating The Prospects Of A Possible Acquisition
Article By: Dr. Hung Tran
Thursday, January 16, 2020 9:27 AM EDT
Riding robust data, Rubraca is most likely to gain approval for resistant prostate cancer having the BRCA mutation. Here I present a scientific analysis to merger and acquisition to give you more insight into Clovis.
In this article: CLVS Also: AZN, BMY, GSK, MRK, RHHBY, JUNO, KITE, CORI, TSRO
Read
GSK Prescribes A US$3.5bn Bond In Three Parts
Article By: Interactive Brokers
Tuesday, March 19, 2019 3:06 PM EDT
British pharma GlaxoSmithKline joined the recent groundswell of high-grade corporate bond issuers Monday to sell new debt.
In this article: GSK Also: NVS, PFE, GILD, BMY, CELG, JUNO, WBA, MSFT, AAPL
Read

Latest Tweets for $JUNO

No tweets yet!

$JUNO

Biotech is Hot Sparked By Biotech M&A Deals for Juno and Bioverativ
Bill Johnson 1/22/2018 9:26:27 PM

I can't believe how high $JUNO has gone up since I've sold it. Big mistake.

Juno Therapeutics Shares Sky Rocket Following Buyout For $9 Billion
Bill Johnson 1/22/2018 8:43:38 PM

I can't believe I used to own this stock. Sold too soon! $JUNO

Biotech Buzz Is Broken
Alpha Stockman 4/29/2015 7:09:10 PM

$KITE opened pretty good, $JUNO needs a bounce

1 to 3 of 3 comments